Béatrice Bonnet

Title: Béatrice Bonnet: Innovator in Pharmaceutical Modulation

Introduction

Béatrice Bonnet is a notable inventor based in Saint-Julien-en-Genevois, France. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate metabotropic glutamate receptors. With a total of three patents to his name, Bonnet's work is pivotal in addressing central nervous system disorders.

Latest Patents

Bonnet's latest patents include a mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyridine, known as dipraglurant. This invention relates to both crystalline and amorphous forms of the compound, which serve as negative allosteric modulators of the MGLU5 receptor. The compounds are designed for the treatment or prevention of various central nervous system disorders. Another significant patent involves alkynyl derivatives that act as modulators of metabotropic glutamate receptors, specifically subtype 5 (mGluR5). These compounds are also aimed at treating central nervous system disorders and other related conditions.

Career Highlights

Béatrice Bonnet is currently associated with Addex Pharma, S.A., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for patients suffering from disorders linked to mGlu receptors.

Collaborations

Bonnet collaborates with esteemed colleagues such as Anne-Sophie Bessis and Christelle Bolea, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Béatrice Bonnet's contributions to pharmaceutical modulation through his patents and collaborations highlight his role as a key inventor in the field. His work continues to pave the way for new treatments for central nervous system disorders.